It wont hurt, but the only thing that is going to make this fly is an out-licensing deal.
Duthy has repeatedly spruiked NEU's commercial strategy for Daybue which was the same. Fully support this commercial direction (or M&A or equity) in the US, EU and Asian markets.
Their decision to retain 100% commercial ownership of NTI164 assets in Australia is one with some risk and cost presumably - but may be shortened by the provisional registration pathway process.
- Forums
- ASX - By Stock
- Ann: US FDA orphan drug designation requested for Rett Syndrome
It wont hurt, but the only thing that is going to make this fly...
Featured News
Add NTI (ASX) to my watchlist
(20min delay)
|
|||||
Last
4.9¢ |
Change
0.000(0.00%) |
Mkt cap ! $50.69M |
Open | High | Low | Value | Volume |
4.9¢ | 5.0¢ | 4.9¢ | $95.05K | 1.922M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 471513 | 4.9¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
5.0¢ | 122727 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 471513 | 0.049 |
3 | 520000 | 0.048 |
4 | 221600 | 0.047 |
4 | 1768152 | 0.046 |
1 | 22240 | 0.045 |
Price($) | Vol. | No. |
---|---|---|
0.050 | 122727 | 2 |
0.051 | 100000 | 1 |
0.053 | 330000 | 3 |
0.054 | 95800 | 1 |
0.057 | 80000 | 1 |
Last trade - 16.10pm 07/10/2024 (20 minute delay) ? |
Featured News
NTI (ASX) Chart |